APPLICATION
ANDA214673
TYPE
ANDA
ORIGINAL APPROVAL
2023-11-20
LATEST ACTION
2024-11-13
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued
Products
LEVETIRACETAMDiscontinued
LEVETIRACETAM 100MG/ML · SOLUTION · ORAL
Approval history
2024-11-13Labeling · Supplement 2 · standardAP
2024-11-13Labeling · Supplement 1 · standardAP
2023-11-20UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.